Noile-Immune Biotech (TSE:4893) Debt-to-Equity : 0.00 (As of Mar. 2024)

Noile-Immune Biotech Debt-to-Equity Chart

Noile-Immune Biotech Quarterly Data
	Dec20	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial				N/A	-	-	-	-

Competitive Comparison of Noile-Immune Biotech's Debt-to-Equity

For the Biotechnology subindustry, Noile-Immune Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Noile-Immune Biotech's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Noile-Immune Biotech's Debt-to-Equity falls into.

Noile-Immune Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Noile-Immune Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Noile-Immune Biotech's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noile-Immune Biotech  (TSE:4893) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Noile-Immune Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Noile-Immune Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Noile-Immune Biotech (TSE:4893) Business Description